MA
Therapeutic Areas
Innovent Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tyvyt (sintilimab) | Various Cancers | Approved |
| Byvasda (bevacizumab biosimilar) | Various Cancers | Approved |
| IBI-306 | Hypercholesterolemia | NDA Submitted |
| IBI-362 | Type 2 Diabetes/Obesity | Phase 3 |
| IBI-310 | Various Cancers | Phase 3 |
| IBI-326 | Multiple Myeloma | Phase 1/2 |
| IBI-322 | Advanced Solid Tumors | Phase 1/2 |
| IBI-323 | Advanced Solid Tumors | Phase 1/2 |